AG˹ٷ

STOCK TITAN

[Form 4] Zai Lab Limited American Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Du Ying, Chairperson & CEO of Zai Lab Ltd (ZLAB), reported option exercises and open-market sales under a Rule 10b5-1 plan. The Form 4 shows acquisitions (code M) on 08/12/2025 and 08/13/2025 of 50,000 and 46,387 American Depositary Shares (ADS) equivalents at a stated price of $0.60 (reflecting stock options). The reporting person sold the same amounts on those dates under the 10b5-1 plan for weighted average prices of $34.2511 and $35.4687 respectively. Following the transactions the filing reports 536,962 ADS beneficially owned. The filing notes the stock options fully vested on 10/22/2020 and the 10b5-1 plan was adopted on 11/20/2024.

Du Ying, Presidente e CEO di Zai Lab Ltd (ZLAB), ha comunicato l'esercizio di opzioni e vendite sul mercato aperto nell'ambito di un piano Rule 10b5-1. Il Modulo 4 indica acquisizioni (codice M) in data 12/08/2025 e 13/08/2025 rispettivamente di 50.000 e 46.387 azioni depositarie americane (ADS) in equivalenza, a un prezzo indicato di $0,60 (riflettente opzioni su azioni). La persona segnalante ha venduto le stesse quantità in quelle date ai sensi del piano 10b5-1 a prezzi medi ponderati di $34,2511 e $35,4687 rispettivamente. Dopo le operazioni il documento riporta la detenzione beneficiaria di 536.962 ADS. Si segnala che le opzioni sono completamente maturate il 22/10/2020 e che il piano 10b5-1 è stato adottato il 20/11/2024.

Du Ying, presidenta y CEO de Zai Lab Ltd (ZLAB), informó la ejecución de opciones y ventas en el mercado abierto bajo un plan Rule 10b5-1. El Formulario 4 muestra adquisiciones (código M) el 12/08/2025 y el 13/08/2025 de 50.000 y 46.387 acciones depositarias americanas (ADS) equivalentes a un precio declarado de $0.60 (correspondiente a opciones sobre acciones). La persona informante vendió las mismas cantidades en esas fechas bajo el plan 10b5-1 a precios promedio ponderados de $34.2511 y $35.4687, respectivamente. Tras las transacciones, la presentación informa la tenencia beneficiaria de 536.962 ADS. El documento indica que las opciones se consolidaron por completo el 22/10/2020 y que el plan 10b5-1 se adoptó el 20/11/2024.

자이 �(Zai Lab Ltd, ZLAB) 회장이자 CEO� 두잉(Du Ying)은 Rule 10b5-1 계획� 따른 스톡옵션 행사 � 장내 매도� 보고했습니다. Form 4에는 2025� 8� 12� � 8� 13일에 각각 50,000주와 46,387주에 해당하는 미국예탁�(ADS) 등가 취득(코드 M)� 명시되어 있으�, 표기 가격은 $0.60(스톡옵션 반영)입니�. 보고자는 동일 수량� 해당일에 10b5-1 계획� 따라 가중평� 가� $34.2511 � $35.4687� 매도했습니다. 거래 이후 제출서는 536,962 ADS� 실질적으� 보유하고 있다� 보고합니�. 제출서에� 스톡옵션� 2020� 10� 22일에 완전� 베스팅되었고 10b5-1 계획은 2024� 11� 20일에 채택되었다고 명시되어 있습니다.

Du Ying, présidente et CEO de Zai Lab Ltd (ZLAB), a déclaré l'exercice d'options et des ventes sur le marché libre dans le cadre d'un plan Rule 10b5-1. Le formulaire 4 indique des acquisitions (code M) les 12/08/2025 et 13/08/2025 de 50 000 et 46 387 équivalents d'American Depositary Shares (ADS) à un prix déclaré de 0,60 $ (reflétant des options sur actions). La personne déclarante a vendu les mêmes montants ces jours-là au titre du plan 10b5-1 à des prix moyens pondérés de 34,2511 $ et 35,4687 $ respectivement. À la suite des opérations, le dépôt fait état d'une détention bénéficiaire de 536 962 ADS. Le document précise que les options ont entièrement acquis leurs droits le 22/10/2020 et que le plan 10b5-1 a été adopté le 20/11/2024.

Du Ying, Vorsitzende und CEO von Zai Lab Ltd (ZLAB), meldete die Ausübung von Optionen und Verkäufe am offenen Markt im Rahmen eines Rule 10b5-1-Plans. Das Formular 4 weist Erwerbe (Code M) am 12.08.2025 und 13.08.2025 über jeweils 50.000 bzw. 46.387 American Depositary Shares (ADS)-Äquivalente zu einem angegebenen Preis von $0,60 (als Folge von Aktienoptionen) aus. Die meldepflichtige Person veräußerte dieselben Stückzahlen an diesen Tagen gemäß dem 10b5-1-Plan zu gewichteten Durchschnittspreisen von $34,2511 bzw. $35,4687. Nach den Transaktionen meldet die Einreichung einen wirtschaftlichen Besitz von 536.962 ADS. Weiterhin wird angegeben, dass die Aktienoptionen am 22.10.2020 vollständig unverfallbar wurden und der 10b5-1-Plan am 20.11.2024 angenommen wurde.

Positive
  • Transactions executed under a Rule 10b5-1 plan, indicating preplanned and documented insider trading activity.
  • Stock options fully vested as of 10/22/2020, showing no recent acceleration or special vesting disclosed in this filing.
  • Reporting person retains substantial ownership with 536,962 ADS beneficially owned after the transactions.
Negative
  • Insider sold a total of 96,387 ADS equivalents (50,000 and 46,387) on 08/12/2025 and 08/13/2025, which is material selling activity.
  • Weighted average sale prices were $34.2511 and $35.4687, indicating the insider realized significant proceeds from the sales.

Insights

TL;DR: Insider exercised long-held options and sold shares via a documented 10b5-1 plan, showing routine executive liquidity and compliance.

The Form 4 discloses that Du Ying exercised stock options with a $0.60 exercise price and concurrently sold equivalent ADS amounts on 08/12/2025 and 08/13/2025 under a Rule 10b5-1 plan adopted 11/20/2024. The filing states the options fully vested in 2020, which reduces governance concerns over opportunistic timing. Use of a 10b5-1 plan and attorney-in-fact signature indicate procedural adherence and preplanned execution rather than ad hoc insider trading.

TL;DR: Insider sales were material in size but appear executed through a pre-established plan; net ownership remains substantial.

The transactions consist of 96,387 ADS equivalents sold at weighted average prices of $34.2511 and $35.4687 and reporting of 536,962 ADS beneficially owned after the trades. Exercising options at $0.60 and immediate sales generated realized proceeds at market prices noted in the filing. These are straightforward option exercises and sales; the filing provides weighted-average sale prices and offers to furnish per-price details to SEC staff or holders, supporting transparency for investors.

Du Ying, Presidente e CEO di Zai Lab Ltd (ZLAB), ha comunicato l'esercizio di opzioni e vendite sul mercato aperto nell'ambito di un piano Rule 10b5-1. Il Modulo 4 indica acquisizioni (codice M) in data 12/08/2025 e 13/08/2025 rispettivamente di 50.000 e 46.387 azioni depositarie americane (ADS) in equivalenza, a un prezzo indicato di $0,60 (riflettente opzioni su azioni). La persona segnalante ha venduto le stesse quantità in quelle date ai sensi del piano 10b5-1 a prezzi medi ponderati di $34,2511 e $35,4687 rispettivamente. Dopo le operazioni il documento riporta la detenzione beneficiaria di 536.962 ADS. Si segnala che le opzioni sono completamente maturate il 22/10/2020 e che il piano 10b5-1 è stato adottato il 20/11/2024.

Du Ying, presidenta y CEO de Zai Lab Ltd (ZLAB), informó la ejecución de opciones y ventas en el mercado abierto bajo un plan Rule 10b5-1. El Formulario 4 muestra adquisiciones (código M) el 12/08/2025 y el 13/08/2025 de 50.000 y 46.387 acciones depositarias americanas (ADS) equivalentes a un precio declarado de $0.60 (correspondiente a opciones sobre acciones). La persona informante vendió las mismas cantidades en esas fechas bajo el plan 10b5-1 a precios promedio ponderados de $34.2511 y $35.4687, respectivamente. Tras las transacciones, la presentación informa la tenencia beneficiaria de 536.962 ADS. El documento indica que las opciones se consolidaron por completo el 22/10/2020 y que el plan 10b5-1 se adoptó el 20/11/2024.

자이 �(Zai Lab Ltd, ZLAB) 회장이자 CEO� 두잉(Du Ying)은 Rule 10b5-1 계획� 따른 스톡옵션 행사 � 장내 매도� 보고했습니다. Form 4에는 2025� 8� 12� � 8� 13일에 각각 50,000주와 46,387주에 해당하는 미국예탁�(ADS) 등가 취득(코드 M)� 명시되어 있으�, 표기 가격은 $0.60(스톡옵션 반영)입니�. 보고자는 동일 수량� 해당일에 10b5-1 계획� 따라 가중평� 가� $34.2511 � $35.4687� 매도했습니다. 거래 이후 제출서는 536,962 ADS� 실질적으� 보유하고 있다� 보고합니�. 제출서에� 스톡옵션� 2020� 10� 22일에 완전� 베스팅되었고 10b5-1 계획은 2024� 11� 20일에 채택되었다고 명시되어 있습니다.

Du Ying, présidente et CEO de Zai Lab Ltd (ZLAB), a déclaré l'exercice d'options et des ventes sur le marché libre dans le cadre d'un plan Rule 10b5-1. Le formulaire 4 indique des acquisitions (code M) les 12/08/2025 et 13/08/2025 de 50 000 et 46 387 équivalents d'American Depositary Shares (ADS) à un prix déclaré de 0,60 $ (reflétant des options sur actions). La personne déclarante a vendu les mêmes montants ces jours-là au titre du plan 10b5-1 à des prix moyens pondérés de 34,2511 $ et 35,4687 $ respectivement. À la suite des opérations, le dépôt fait état d'une détention bénéficiaire de 536 962 ADS. Le document précise que les options ont entièrement acquis leurs droits le 22/10/2020 et que le plan 10b5-1 a été adopté le 20/11/2024.

Du Ying, Vorsitzende und CEO von Zai Lab Ltd (ZLAB), meldete die Ausübung von Optionen und Verkäufe am offenen Markt im Rahmen eines Rule 10b5-1-Plans. Das Formular 4 weist Erwerbe (Code M) am 12.08.2025 und 13.08.2025 über jeweils 50.000 bzw. 46.387 American Depositary Shares (ADS)-Äquivalente zu einem angegebenen Preis von $0,60 (als Folge von Aktienoptionen) aus. Die meldepflichtige Person veräußerte dieselben Stückzahlen an diesen Tagen gemäß dem 10b5-1-Plan zu gewichteten Durchschnittspreisen von $34,2511 bzw. $35,4687. Nach den Transaktionen meldet die Einreichung einen wirtschaftlichen Besitz von 536.962 ADS. Weiterhin wird angegeben, dass die Aktienoptionen am 22.10.2020 vollständig unverfallbar wurden und der 10b5-1-Plan am 20.11.2024 angenommen wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Du Ying

(Last) (First) (Middle)
C/O ZAI LAB LIMITED
314 MAIN STREET, 4TH FLOOR, SUITE 100

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Zai Lab Ltd [ ZLAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairperson & CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares(1) 08/12/2025 M 50,000 A $0.6 586,962 D
American Depositary Shares(1) 08/12/2025 S(2) 50,000 D $34.2511(3) 536,962 D
American Depositary Shares(1) 08/13/2025 M 46,387 A $0.6 583,349 D
American Depositary Shares(1) 08/13/2025 S(2) 46,387 D $35.4687(4) 536,962 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $0.6 08/12/2025 M 50,000 (5) 10/22/2025 American Depositary Shares(1) 50,000 $0 46,387 D
Stock Options (Right to Buy) $0.6 08/13/2025 M 46,387 (5) 10/22/2025 American Depositary Shares(1) 46,387 $0 0 D
Explanation of Responses:
1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
2. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2024.
3. Reflects a weighted average sale price of $34.2511 per share, at prices ranging from $33.70 to $34.60 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
4. Reflects a weighted average sale price of $35.4687 per share, at prices ranging from $34.845 to $35.80 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
5. The Stock Options fully vested as of October 22, 2020.
/s/ Bruce Blefeld, Attorney-in-Fact 08/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for ZLAB and what is their role?

The Form 4 was filed by Du Ying, who is listed as Chairperson & CEO of Zai Lab Ltd.

What transactions are reported on the 08/12/2025 and 08/13/2025 Form 4 for ZLAB?

The filing reports acquisitions (code M) of 50,000 ADS on 08/12/2025 and 46,387 ADS on 08/13/2025 at a $0.60 price (stock options), and sales of those same amounts at weighted average prices of $34.2511 and $35.4687 respectively.

Was the insider trading executed under a pre-established plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on 11/20/2024 as stated in the filing.

How many ADS does the reporting person beneficially own after these transactions?

The Form 4 reports 536,962 ADS beneficially owned by the reporting person following the reported transactions.

When did the stock options involved vest?

The filing states the stock options fully vested on 10/22/2020.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

3.96B
106.54M
1.42%
50.94%
3.61%
Biotechnology
Pharmaceutical Preparations
China
SHANGHAI